GPCR (Structure Corp) Earnings growth in current year

GPCR (Structure Corp) - company brandmark

Structure Therapeutics is actively recruiting leading endocrinologists, retaining staff through generous stock options. The company is developing oral diabetes treatments, aiming to replace injections with convenient pills. Its technologies rely on AI modeling for molecular design. By comparing the annual percentage dynamics of earnings per share on GURU.Markets, we see that the value of -111.00 expresses the metric level.

GPCR: Structure Therapeutics Earnings per share growth in current year 04/28/2023 - 11/10/2026

Financial and market metric breakdowns for Structure Therapeutics (GPCR)

- share price and expert price forecast:
Price Structure Therapeutics Inc|GPCR - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Structure Corp|GPCR - Enterprise Value
- book capitalization data:
Net Assets per Single Share Structure Therapeutics|GPCR - Company Book Value|Market-to-Book Ratio structuretx.com|GPCR - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Equity Structure Therapeutics|GPCR - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient structuretx.com|GPCR - Company Debts|Debts to Net Assets Structure Corp|GPCR - Company Long-Term Debt|Company Current Liabilities Structure Therapeutics|Interim Coverage Ratio structuretx.com
- earnings and valuation multiples information:
GPCR - Net Income|Future Net Profit Structure Therapeutics|GPCR - Price to Earnings Ratio|Future Price to Earnings Multiple Structure Corp|GPCR - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Structure Corp|GPCR - Operating profit EBITDA|Net earnings per share for the last 12 months Structure Therapeutics|GPCR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months structuretx.com|GPCR - Net earnings per share growth this year|Earnings growth forecast for next year Structure Therapeutics
Basic company analysis:GPCR - Structure Therapeutics Inc
Finished products of Structure Therapeutics Inc.

Challenges with international research and raw material logistics for metabolic drugs are directly reflected in the profit dynamics of Structure Therapeutics (GPCR). The current year-over-year EPS percentage deviation of -111.00 measures the rate of change in net income per share, allowing investors to assess the efficiency of the company's operating model amid geopolitical barriers and currency fluctuations.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Pharma) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics Corp|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (akerotx.com)|Earnings per share growth in current year Metsera MTSR|MoonLake Immunotherapeutics AG (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio|Agios (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year MiMedx Group (MDXG)|Net earnings per share growth this year Rezolute Bio RZLT|Earnings per share growth in current year Lexicon Pharmaceuticals LXRX|Expected net earnings per share growth this year mbxbio.com (MBX)|ALT: Net earnings per share growth this year|Aardvark Therapeutics Inc. - Net earnings per one share growth for the current year|Sagimet (SGMT) - Earnings per share growth in current year|BioAge Labs, Inc - Earnings per share increase in current year|Net earnings per share growth this year BMEA|Earnings growth in current year Quince|Earnings growth in current year GUTS|Net earnings per share growth this year vtvtherapeutics.com VTVT|Agape ATP - Net earnings per share growth this year|Net earnings per one share growth for the current year PLUR (Pluristem Therapeutics)|SYBX: Net earnings per share growth this year|LPCN - Earnings growth in current year|matinasbiopharma.com (MTNB) - Earnings per share growth in current year|sprucebiosciences.com - Earnings per share increase in current year|GLTO (Galecto Corp) - Earnings growth in current year|Earnings per share growth rate in current year Carmell Therapeutics CTCX|Net earnings per share growth this year LUMO (Lumos Pharma, Inc.)|ONVO (organovo.com) - Earnings per share increase in current year|Radius Recycling - Net earnings per share growth this year